Bosseray N
Br J Exp Pathol. 1978 Aug;59(4):354-65.
Immunity to Brucella in the mouse, assessed by bacterial spleen counts 15 days after intraperitoneal inoculation of a standard challenge of B. abortus 544, has been studied with two vaccines, one experimental, composed of a fraction of the bacterial cell-wall (F8) extracted from B. abortus 99, the other of killed whole bacteria, B. melitensis 53 H38, taken as reference (H38). The level of primary immunity depended on the dose of vaccine, the presence of oil adjuvant and the age of the mouse. The presence of adjuvant enabled the immunization to F8 to continue beyond the first month, to reach its maximum around the fourth month, and to remain stable for at least 7 months. A booster injection 3 or 6 months after the primary vaccination reinforced existing immunity but did not increase it beyond a certain level. The effect of the recall injection was clearly demonstrated with low doses which gave a lower level of primary immunity.
通过腹腔接种流产布鲁氏菌544标准攻击剂量15天后的细菌脾脏计数来评估小鼠对布鲁氏菌的免疫力,使用了两种疫苗进行研究,一种是实验性疫苗,由从流产布鲁氏菌99中提取的细菌细胞壁组分(F8)组成,另一种是作为对照的灭活全菌疫苗,即羊种布鲁氏菌53 H38(H38)。初次免疫水平取决于疫苗剂量、油佐剂的存在以及小鼠的年龄。佐剂的存在使对F8的免疫能持续超过第一个月,在第四个月左右达到最大值,并至少稳定7个月。初次接种疫苗3或6个月后进行加强注射可增强现有的免疫力,但不会使其超过一定水平。对于初次免疫水平较低的低剂量疫苗,再次注射的效果得到了明显证明。